{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:57:01Z","timestamp":1770501421151,"version":"3.49.0"},"reference-count":52,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":172,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2001,7]]},"abstract":"<jats:p>The HIV associated lipodystrophy syndrome is characterized by fat loss from the periphery, fat accumulation in the abdominal, dorsocervical regions and breasts, and hyperlipidaemia, insulin resistance and lactic acidaemia. Although several mechanisms have been proposed to explain these abnormalities, the exact aetiology of the condition remains unclear and will likely prove to be complex. The principal clinical concerns that arise from this disorder are possible increased risks of premature atherosclerosis and cardiovascular disease. A variety of therapeutic interventions, designed to limit these risks, are under evaluation.<\/jats:p>","DOI":"10.1046\/j.1468-1293.2001.00071.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T00:19:38Z","timestamp":1047428378000},"page":"166-173","source":"Crossref","is-referenced-by-count":46,"title":["HIV\u2010associated lipodystrophy"],"prefix":"10.1111","volume":"2","author":[{"given":"PWG","family":"Mallon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DA","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(97)11518-5"},{"key":"e_1_2_7_4_2","unstructured":"WardDJ DelaneyKM MoormanACet al.Description of lipodystrophy in HIV Outpatients Study (HOPS).International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.San Diego CA June 1999[Abstract 10]."},{"key":"e_1_2_7_5_2","unstructured":"MillerJE EmeryS FrenchM BakerD CooperDA.The Australian prevalence survey of lipodystrophy syndrome.VII Conference on Retroviruses and Opportunistic Infections.San Francisco CA January 2000[Abstract 201]."},{"key":"e_1_2_7_6_2","unstructured":"BoubakerK SudreP FleppMet al.Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study.VII Conference on Retroviruses and Opportunistic InfectionsSan Francisco CA January 2000[Abstract 57]."},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)04056-3"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1006\/bcon.1998.0668"},{"key":"e_1_2_7_9_2","unstructured":"NoorM LoJ MulliganKet al.Metabolic effects of indinavir in healthy HIV\u2010seronegative subjects.II International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.Toronto Canada September 2000[Abstract O10:8]."},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.13.2050"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(98)03391-1"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/317426"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-188507000-00006"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1430565"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(99)00414-3"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(99)06102-4"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.164R007"},{"key":"e_1_2_7_18_2","unstructured":"ParkerRA MeyersDS AndrewsBA FlintOP DurhamSK.Effects of nucleoside reverse transcriptase inhibitors and HIV protease inhibitors on adipogenesis and adipocyte metabolism.II International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.Toronto Canada September 2000[Abstract O4:4]."},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199814000-00004"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200002180-00001"},{"key":"e_1_2_7_21_2","unstructured":"ShikumaC HuN MilneCet al.Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV infected individuals with peripheral lipoatrophy.AIDSin press."},{"key":"e_1_2_7_22_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1242\/jcs.114.1.9","article-title":"Lamins in disease: why do ubiquitously expressed nuclear envelope proteins give rise to tissue\u2010specific disease phenotypes?","volume":"114","author":"Hutchison C","year":"2000","journal-title":"J Cell Sci"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.147.5.913"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0231(20001015)14:19[#60]1854::aid-rcm102[#62]3.0.co]2-m"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/131.2.354S"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/313854"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1420114"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0166-3542(00)00102-9"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.20.12.2625"},{"key":"e_1_2_7_30_2","unstructured":"EggerM.Metabolic complications of HAART. need for perspective.II International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV.Toronto Canada September 2000[Abstract O23:15]."},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/317541"},{"key":"e_1_2_7_32_2","unstructured":"SmartEJ MatveevS KincerJ GreenbergRN.Protease inhibitors up\u2010regulate SR\u2010BI and HDL\u2010dependent cholesterol uptake in human macrophages: a mechanism that may enhance foam cell formation.VIII Conference on Retroviruses and Opportunistic Infections.Chicago IL February 2001 [Abstract\u2003662]."},{"key":"e_1_2_7_33_2","unstructured":"Mary\u2010KrauseM CotteL PartisaniMet al.Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV\u2010infected men.VIII Conference on Retroviruses and Opportunistic Infections. Chicago IL February 2001 [Abstract 657] ."},{"key":"e_1_2_7_34_2","unstructured":"KleinD HurleyL SorelM SidneyS.Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? Follow\u2010up through June.VIII Conference on Retroviruses and Opportunistic Infections. Chicago IL February 2001 [Abstract\u2003655]."},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.31.10.2426"},{"key":"e_1_2_7_36_2","unstructured":"SosmanJM KleinMA BellehumeurJL AeschlimannSE SteinJH.Endothelial dysfunction is associated with the use of human immunodeficiency virus type 1 protease inhibitors.VII Conference on Retroviruses and Opportunistic Infections.San Francisco CA JanuaryFebruary 2000[Abstract 29]."},{"key":"e_1_2_7_37_2","unstructured":"CheminotN GariepyJ ChironiGet al.Diagnosis and determinants of subclinical arterial disease in HIV1\u2010infected patients on HAART.VII Conference on Retroviruses and Opportunistic Infections.San Francisco CA JanuaryFebruary 2000[Abstract 31]."},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1099-131x(199607)15:4[#60]329::aid-for610[#62]3.0.co]2-w"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0953-6205(00)00103-5"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.4.472"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-9136(199611)13:11[#60]1000::aid-dia169[#62]3.0.co]2-3"},{"key":"e_1_2_7_42_2","unstructured":"MillerJ CarrA BrownD CooperDA.A randomised double\u2010blind study of gemfibrozil (GF) for the treatment of protease inhibitor\u2010associated hypertriglyceridaemia.VIII Conference on Retroviruses and Opportunistic Infections.Chicago IL February 2001 [Abstract 540]."},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-4-200008150-00009"},{"key":"e_1_2_7_44_2","unstructured":"WalliRK MichlGM BognerJR GoebelFD.Effects of the PPAR\u2010activator troglitazone on protease inhibitor associated peripheral insulin resistance.VI Conference on Retroviruses and Opportunistic Infections.Chicago IL January\u2013February 1999 [Abstract 673]."},{"key":"e_1_2_7_45_2","unstructured":"CarrA HudsonJ ChuahJet al.HIV protease inhibitor substitution in patients with lipodystrophy: a randomised controlled open\u2010label multicentre study.AIDS in press."},{"key":"e_1_2_7_46_2","unstructured":"TebasP YarasheskiWG PowderlyEet al.A prospective open\u2010label trial of a maintenance nevirapine (NVP)\u2010containing regimen in patients with undetectable viral loads (VL) on protease inhibitor (PI) regimens for at least 6 months.VII Conference on Retroviruses and Opportunistic Infections.San Francisco CA January\u2013February 2000 [Abstract 45]."},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/317477"},{"key":"e_1_2_7_48_2","unstructured":"MartinezE RomeuJ Garcia\u2010ViejoMAet al.An open randomised study on the replacement of HIV\u20101 protease inhibitors by efavirenz in chronically suppressed HIV\u20101\u2010infected patients with lipodystrophy.VIII Conference on Retroviruses and Opportunistic Infections.Chicago IL February 2001 [Abstract 668]."},{"key":"e_1_2_7_49_2","doi-asserted-by":"crossref","unstructured":"WalliR HusterK BognerJRet al.Switching from PI to ABC improves insulin sensitivity and fasting lipids \u2013 12 month follow\u2010up.VIII Conference on Retroviruses and Opportunistic Infections.Chicago IL February 2001 [Abstract 672].","DOI":"10.2165\/00128413-200112780-00029"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7901"},{"issue":"4","key":"e_1_2_7_51_2","first-page":"S54 [Abstract P","article-title":"Metabolic and morphological alterations under antiretroviral therapy: preliminary results of lipodystrophy Italian Multicentre Study (LIMS)","volume":"14","author":"Galli M","year":"2000","journal-title":"AIDS"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1088\/0022-3700\/13\/10\/016"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1116\/1.589207"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1468-1293.2001.00071.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1468-1293.2001.00071.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1468-1293.2001.00071.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:17:56Z","timestamp":1697617076000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1468-1293.2001.00071.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["10.1046\/j.1468-1293.2001.00071.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1468-1293.2001.00071.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}